RhumbLine Advisers’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $249M | Buy |
8,875,485
+65,632
| +0.7% | +$1.75M | 0.21% | 73 |
|
|
2025
Q4 | $219M | Sell |
8,809,853
-217,332
| -2% | -$5.48M | 0.18% | 88 |
|
|
2025
Q3 | $230M | Buy |
9,027,185
+6,585
| +0.1% | +$163K | 0.18% | 86 |
|
|
2025
Q2 | $219M | Sell |
9,020,600
-439,036
| -5% | -$10.2M | 0.19% | 89 |
|
|
2025
Q1 | $240M | Sell |
9,459,636
-213,511
| -2% | -$5.59M | 0.22% | 77 |
|
|
2024
Q4 | $257M | Sell |
9,673,147
-55,458
| -0.6% | -$1.5M | 0.23% | 69 |
|
|
2024
Q3 | $282M | Sell |
9,728,605
-229,522
| -2% | -$6.7M | 0.25% | 66 |
|
|
2024
Q2 | $279M | Sell |
9,958,127
-35,424
| -0.4% | -$975K | 0.26% | 59 |
|
|
2024
Q1 | $277M | Sell |
9,993,551
-302,286
| -3% | -$8.39M | 0.27% | 58 |
|
|
2023
Q4 | $296M | Sell |
10,295,837
-127,657
| -1% | -$3.86M | 0.31% | 49 |
|
|
2023
Q3 | $346M | Buy |
10,423,494
+116,428
| +1% | +$4.12M | 0.4% | 36 |
|
|
2023
Q2 | $378M | Buy |
10,307,066
+153,664
| +2% | +$5.98M | 0.42% | 33 |
|
|
2023
Q1 | $414M | Buy |
10,153,402
+390,520
| +4% | +$16.9M | 0.51% | 27 |
|
|
2022
Q4 | $500M | Buy |
9,762,882
+377,345
| +4% | +$18.1M | 0.67% | 20 |
|
|
2022
Q3 | $411M | Buy |
9,385,537
+120,422
| +1% | +$5.85M | 0.61% | 21 |
|
|
2022
Q2 | $486M | Buy |
9,265,115
+509,399
| +6% | +$26M | 0.71% | 19 |
|
|
2022
Q1 | $453M | Buy |
8,755,716
+148,187
| +2% | +$7.69M | 0.58% | 21 |
|
|
2021
Q4 | $508M | Buy |
8,607,529
+34,698
| +0.4% | +$1.72M | 0.62% | 18 |
|
|
2021
Q3 | $369M | Buy |
8,572,831
+188,970
| +2% | +$8.37M | 0.5% | 28 |
|
|
2021
Q2 | $328M | Sell |
8,383,861
-608,030
| -7% | -$23.6M | 0.43% | 34 |
|
|
2021
Q1 | $326M | Sell |
8,991,891
-439,043
| -5% | -$15.6M | 0.44% | 34 |
|
|
2020
Q4 | $347M | Sell |
9,430,934
-457,043
| -5% | -$16.8M | 0.48% | 32 |
|
|
2020
Q3 | $344M | Buy |
9,887,977
+95,877
| +1% | +$3.36M | 0.54% | 32 |
|
|
2020
Q2 | $304M | Buy |
9,792,100
+483,484
| +5% | +$16.4M | 0.51% | 34 |
|
|
2020
Q1 | $288M | Buy |
9,308,616
+58,612
| +0.6% | +$2M | 0.6% | 28 |
|
|
2019
Q4 | $344M | Buy |
9,250,004
+8,334
| +0.1% | +$297K | 0.58% | 28 |
|
|
2019
Q3 | $315M | Sell |
9,241,670
-181,760
| -2% | -$6.61M | 0.58% | 29 |
|
|
2019
Q2 | $387M | Sell |
9,423,430
-294,035
| -3% | -$11.7M | 0.73% | 21 |
|
|
2019
Q1 | $392M | Sell |
9,717,465
-242,713
| -2% | -$9.72M | 0.76% | 20 |
|
|
2018
Q4 | $412M | Buy |
9,960,178
+119,636
| +1% | +$4.97M | 0.9% | 11 |
|
|
2018
Q3 | $411M | Sell |
9,840,542
-161,393
| -2% | -$6.21M | 0.79% | 17 |
|
|
2018
Q2 | $344M | Sell |
10,001,935
-211,438
| -2% | -$7.23M | 0.69% | 21 |
|
|
2018
Q1 | $344M | Sell |
10,213,373
-53,749
| -0.5% | -$1.85M | 0.72% | 19 |
|
|
2017
Q4 | $353M | Buy |
10,267,122
+270,825
| +3% | +$9.23M | 0.72% | 20 |
|
|
2017
Q3 | $339M | Sell |
9,996,297
-166,718
| -2% | -$5.36M | 0.74% | 19 |
|
|
2017
Q2 | $324M | Sell |
10,163,015
-97,648
| -1% | -$3.08M | 0.74% | 17 |
|
|
2017
Q1 | $333M | Buy |
10,260,663
+280,431
| +3% | +$8.84M | 0.78% | 18 |
|
|
2016
Q4 | $308M | Buy |
9,980,232
+388,021
| +4% | +$11.8M | 0.78% | 18 |
|
|
2016
Q3 | $308M | Buy |
9,592,211
+395,888
| +4% | +$13.2M | 0.85% | 17 |
|
|
2016
Q2 | $307M | Buy |
9,196,323
+485,405
| +6% | +$15.5M | 0.91% | 16 |
|
|
2016
Q1 | $245M | Buy |
8,710,918
+339,694
| +4% | +$9.7M | 0.76% | 19 |
|
|
2015
Q4 | $256M | Sell |
8,371,224
-30,970
| -0.4% | -$974K | 0.83% | 16 |
|
|
2015
Q3 | $250M | Buy |
8,402,194
+130,941
| +2% | +$4.2M | 0.85% | 15 |
|
|
2015
Q2 | $263M | Sell |
8,271,253
-1,594,178
| -16% | -$52M | 0.84% | 12 |
|
|
2015
Q1 | $326M | Sell |
9,865,431
-150,123
| -1% | -$4.77M | 0.94% | 12 |
|
|
2014
Q4 | $296M | Sell |
10,015,554
-177,834
| -2% | -$5.1M | 0.86% | 14 |
|
|
2014
Q3 | $286M | Sell |
10,193,388
-252,940
| -2% | -$7.1M | 0.86% | 17 |
|
|
2014
Q2 | $294M | Sell |
10,446,328
-641,819
| -6% | -$18.3M | 0.86% | 16 |
|
|
2014
Q1 | $338M | Buy |
11,088,147
+158,732
| +1% | +$4.73M | 1% | 14 |
|
|
2013
Q4 | $318M | Sell |
10,929,415
-541,835
| -5% | -$15.8M | 0.94% | 14 |
|
|
2013
Q3 | $312M | Sell |
11,471,250
-321,320
| -3% | -$8.74M | 0.97% | 14 |
|
|
2013
Q2 | $313M | Buy |
+11,792,570
| New | +$326M | 1.01% | 14 |
|
Other funds holding PFE
VCM
VPM
RhumbLine Advisers's PFE Position: Q1 2026 in Review
RhumbLine Advisers increased its Pfizer (PFE) stake by 0.74% in Q1 2026, buying an estimated $1.75M and bringing the position to 8,875,485 shares worth $249M. The position accounts for 0.21% of the portfolio, ranked #73.
RhumbLine Advisers first reported a position in PFE in Q2 2013 and has held it in 52 quarters since. The position peaked at $508M in Q4 2021. 2,936 funds tracked by Wall St. Rank hold PFE as of Q1 2026.
- RhumbLine Advisers held 8,875,485 shares of Pfizer worth $249M as of Q1 2026.
- RhumbLine Advisers bought 65,632 Pfizer shares in Q1 2026, an estimated $1.75M.
- Pfizer made up 0.21% of RhumbLine Advisers's portfolio in Q1 2026, its #73 holding.
- RhumbLine Advisers first reported a position in Pfizer in Q2 2013 and has held it in 52 quarters since.
- RhumbLine Advisers's Pfizer position peaked at $508M in Q4 2021.
- 2,936 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.
Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.